Please provide your email address to receive an email when new articles are posted on . TNF inhibitors within 3 years of diagnosis had no statistically significant negative link with colorectal ...

which promotes the release of soluble TNF from its membrane-bound precursor. Inhibitors of this enzyme with drug-like properties have been made and tested in the clinic. These inhibitors include ...

BALTIMORE, February 25, 2025--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed ...

announced that data from the Phase 2a clinical trial of its oral TNF-alpha (TNF-α) inhibitor drug candidate isomyosamine was presented last week in a podium session at the peer-reviewed 15th ...

Isomyosamine is an oral, next-generation TNF-a inhibitor with the potential to transform the way TNF-a based diseases are treated due to its selectivity and ability to cross the blood brain barrier.

Isomyosamine is an oral, next-generation TNF-α inhibitor with the potential to transform the way TNF-α based diseases are treated due to its selectivity and ability to cross the blood brain barrier.

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory ...